

Position statement on the prescribing of Oxycodone and Naloxone combination product

Following the NHS England guidance 'Items which should not routinely be prescribed in primary care: Guidance for CCGs (version 2, June 2019) the following changes to prescribing have been agreed across Barking and Dagenham, Havering and Redbridge.

From 17th September 2019
Barking and Dagenham, Havering and Redbridge Clinical Commissioning Groups (BHR CCGs) no longer supports the prescribing of Oxycodone and Naloxone Combination product

Decision

- The decision to stop Oxycodone and Naloxone combination products applies to ALL patients across Barking and Dagenham, Havering and Redbridge. BHR CCGs have agreed NO exceptions to this recommendation

Please note that Oxycodone remains available to be prescribed where clinically appropriate.

This decision was made because:

- PrescQIPP Community Interest Company (CIC) have issued [a bulletin](#) and did not identify a benefit of Oxycodone and Naloxone in a single product over other analgesia (with laxatives if necessary).
- Due to a significant cost of the Oxycodone and Naloxone combination product and the unclear role of this in therapy compared with individual products
- BHR CCGs have a duty to spend taxpayer's money wisely, to make sure they get the best value possible – especially when NHS funding is being severely squeezed and more patients are being seen with more complex health issues than ever before

Reference:

NHS England and NHS Improvement. Items which should not routinely be prescribed in primary care: Guidance for CCGs. Version 2, June 2019. Publishing approval reference 000608 <https://www.england.nhs.uk/publication/items-which-should-not-be-routinely-prescribed-in-primary-care-guidance-for-ccgs/>